Global Community-acquired Bacterial Pneumonia Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.
LPI (LP Information)' newest research report, the “Community-acquired Bacterial Pneumonia Industry Forecast” looks at past sales and reviews total world Community-acquired Bacterial Pneumonia sales in 2022, providing a comprehensive analysis by region and market sector of projected Community-acquired Bacterial Pneumonia sales for 2023 through 2029. With Community-acquired Bacterial Pneumonia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Community-acquired Bacterial Pneumonia industry.
This Insight Report provides a comprehensive analysis of the global Community-acquired Bacterial Pneumonia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Community-acquired Bacterial Pneumonia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Community-acquired Bacterial Pneumonia market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Community-acquired Bacterial Pneumonia and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Community-acquired Bacterial Pneumonia.
The global Community-acquired Bacterial Pneumonia market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Community-acquired Bacterial Pneumonia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Community-acquired Bacterial Pneumonia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Community-acquired Bacterial Pneumonia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Community-acquired Bacterial Pneumonia players cover Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics, Allergan plc, Bayer AG, Lupin Pharmaceuticals, Mylan N.V., Sanofi S.A. and Pfizer Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Community-acquired Bacterial Pneumonia market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.
LPI (LP Information)' newest research report, the “Community-acquired Bacterial Pneumonia Industry Forecast” looks at past sales and reviews total world Community-acquired Bacterial Pneumonia sales in 2022, providing a comprehensive analysis by region and market sector of projected Community-acquired Bacterial Pneumonia sales for 2023 through 2029. With Community-acquired Bacterial Pneumonia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Community-acquired Bacterial Pneumonia industry.
This Insight Report provides a comprehensive analysis of the global Community-acquired Bacterial Pneumonia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Community-acquired Bacterial Pneumonia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Community-acquired Bacterial Pneumonia market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Community-acquired Bacterial Pneumonia and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Community-acquired Bacterial Pneumonia.
The global Community-acquired Bacterial Pneumonia market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Community-acquired Bacterial Pneumonia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Community-acquired Bacterial Pneumonia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Community-acquired Bacterial Pneumonia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Community-acquired Bacterial Pneumonia players cover Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics, Allergan plc, Bayer AG, Lupin Pharmaceuticals, Mylan N.V., Sanofi S.A. and Pfizer Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Community-acquired Bacterial Pneumonia market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Pleuromutilin Antibiotic
- Cephalosporin
- Glycylcycline
- Oxazolidinone
- Ketolide
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Nabriva Therapeutics
- Paratek Pharmaceuticals
- Melinta Therapeutics
- Allergan plc
- Bayer AG
- Lupin Pharmaceuticals
- Mylan N.V.
- Sanofi S.A.
- Pfizer Inc.
- Dainippon Sumitomo Pharma
- Takeda Pharmaceutical Company Limited
- Basilea Pharmaceutica International AG
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Community-acquired Bacterial Pneumonia Market Size 2018-2029
2.1.2 Community-acquired Bacterial Pneumonia Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Community-acquired Bacterial Pneumonia Segment by Type
2.2.1 Pleuromutilin Antibiotic
2.2.2 Cephalosporin
2.2.3 Glycylcycline
2.2.4 Oxazolidinone
2.2.5 Ketolide
2.2.6 Others
2.3 Community-acquired Bacterial Pneumonia Market Size by Type
2.3.1 Community-acquired Bacterial Pneumonia Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
2.4 Community-acquired Bacterial Pneumonia Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Community-acquired Bacterial Pneumonia Market Size by Application
2.5.1 Community-acquired Bacterial Pneumonia Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
3 COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA MARKET SIZE BY PLAYER
3.1 Community-acquired Bacterial Pneumonia Market Size Market Share by Players
3.1.1 Global Community-acquired Bacterial Pneumonia Revenue by Players (2018-2023)
3.1.2 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Players (2018-2023)
3.2 Global Community-acquired Bacterial Pneumonia Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA BY REGIONS
4.1 Community-acquired Bacterial Pneumonia Market Size by Regions (2018-2023)
4.2 Americas Community-acquired Bacterial Pneumonia Market Size Growth (2018-2023)
4.3 APAC Community-acquired Bacterial Pneumonia Market Size Growth (2018-2023)
4.4 Europe Community-acquired Bacterial Pneumonia Market Size Growth (2018-2023)
4.5 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023)
5.2 Americas Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023)
5.3 Americas Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Community-acquired Bacterial Pneumonia Market Size by Region (2018-2023)
6.2 APAC Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023)
6.3 APAC Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Community-acquired Bacterial Pneumonia by Country (2018-2023)
7.2 Europe Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023)
7.3 Europe Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Community-acquired Bacterial Pneumonia by Region (2018-2023)
8.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023)
8.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA MARKET FORECAST
10.1 Global Community-acquired Bacterial Pneumonia Forecast by Regions (2024-2029)
10.1.1 Global Community-acquired Bacterial Pneumonia Forecast by Regions (2024-2029)
10.1.2 Americas Community-acquired Bacterial Pneumonia Forecast
10.1.3 APAC Community-acquired Bacterial Pneumonia Forecast
10.1.4 Europe Community-acquired Bacterial Pneumonia Forecast
10.1.5 Middle East & Africa Community-acquired Bacterial Pneumonia Forecast
10.2 Americas Community-acquired Bacterial Pneumonia Forecast by Country (2024-2029)
10.2.1 United States Community-acquired Bacterial Pneumonia Market Forecast
10.2.2 Canada Community-acquired Bacterial Pneumonia Market Forecast
10.2.3 Mexico Community-acquired Bacterial Pneumonia Market Forecast
10.2.4 Brazil Community-acquired Bacterial Pneumonia Market Forecast
10.3 APAC Community-acquired Bacterial Pneumonia Forecast by Region (2024-2029)
10.3.1 China Community-acquired Bacterial Pneumonia Market Forecast
10.3.2 Japan Community-acquired Bacterial Pneumonia Market Forecast
10.3.3 Korea Community-acquired Bacterial Pneumonia Market Forecast
10.3.4 Southeast Asia Community-acquired Bacterial Pneumonia Market Forecast
10.3.5 India Community-acquired Bacterial Pneumonia Market Forecast
10.3.6 Australia Community-acquired Bacterial Pneumonia Market Forecast
10.4 Europe Community-acquired Bacterial Pneumonia Forecast by Country (2024-2029)
10.4.1 Germany Community-acquired Bacterial Pneumonia Market Forecast
10.4.2 France Community-acquired Bacterial Pneumonia Market Forecast
10.4.3 UK Community-acquired Bacterial Pneumonia Market Forecast
10.4.4 Italy Community-acquired Bacterial Pneumonia Market Forecast
10.4.5 Russia Community-acquired Bacterial Pneumonia Market Forecast
10.5 Middle East & Africa Community-acquired Bacterial Pneumonia Forecast by Region (2024-2029)
10.5.1 Egypt Community-acquired Bacterial Pneumonia Market Forecast
10.5.2 South Africa Community-acquired Bacterial Pneumonia Market Forecast
10.5.3 Israel Community-acquired Bacterial Pneumonia Market Forecast
10.5.4 Turkey Community-acquired Bacterial Pneumonia Market Forecast
10.5.5 GCC Countries Community-acquired Bacterial Pneumonia Market Forecast
10.6 Global Community-acquired Bacterial Pneumonia Forecast by Type (2024-2029)
10.7 Global Community-acquired Bacterial Pneumonia Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Nabriva Therapeutics
11.1.1 Nabriva Therapeutics Company Information
11.1.2 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Offered
11.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Nabriva Therapeutics Main Business Overview
11.1.5 Nabriva Therapeutics Latest Developments
11.2 Paratek Pharmaceuticals
11.2.1 Paratek Pharmaceuticals Company Information
11.2.2 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Offered
11.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Paratek Pharmaceuticals Main Business Overview
11.2.5 Paratek Pharmaceuticals Latest Developments
11.3 Melinta Therapeutics
11.3.1 Melinta Therapeutics Company Information
11.3.2 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Offered
11.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Melinta Therapeutics Main Business Overview
11.3.5 Melinta Therapeutics Latest Developments
11.4 Allergan plc
11.4.1 Allergan plc Company Information
11.4.2 Allergan plc Community-acquired Bacterial Pneumonia Product Offered
11.4.3 Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Allergan plc Main Business Overview
11.4.5 Allergan plc Latest Developments
11.5 Bayer AG
11.5.1 Bayer AG Company Information
11.5.2 Bayer AG Community-acquired Bacterial Pneumonia Product Offered
11.5.3 Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Bayer AG Main Business Overview
11.5.5 Bayer AG Latest Developments
11.6 Lupin Pharmaceuticals
11.6.1 Lupin Pharmaceuticals Company Information
11.6.2 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Offered
11.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Lupin Pharmaceuticals Main Business Overview
11.6.5 Lupin Pharmaceuticals Latest Developments
11.7 Mylan N.V.
11.7.1 Mylan N.V. Company Information
11.7.2 Mylan N.V. Community-acquired Bacterial Pneumonia Product Offered
11.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Mylan N.V. Main Business Overview
11.7.5 Mylan N.V. Latest Developments
11.8 Sanofi S.A.
11.8.1 Sanofi S.A. Company Information
11.8.2 Sanofi S.A. Community-acquired Bacterial Pneumonia Product Offered
11.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Sanofi S.A. Main Business Overview
11.8.5 Sanofi S.A. Latest Developments
11.9 Pfizer Inc.
11.9.1 Pfizer Inc. Company Information
11.9.2 Pfizer Inc. Community-acquired Bacterial Pneumonia Product Offered
11.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Pfizer Inc. Main Business Overview
11.9.5 Pfizer Inc. Latest Developments
11.10 Dainippon Sumitomo Pharma
11.10.1 Dainippon Sumitomo Pharma Company Information
11.10.2 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Offered
11.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Dainippon Sumitomo Pharma Main Business Overview
11.10.5 Dainippon Sumitomo Pharma Latest Developments
11.11 Takeda Pharmaceutical Company Limited
11.11.1 Takeda Pharmaceutical Company Limited Company Information
11.11.2 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Offered
11.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Takeda Pharmaceutical Company Limited Main Business Overview
11.11.5 Takeda Pharmaceutical Company Limited Latest Developments
11.12 Basilea Pharmaceutica International AG
11.12.1 Basilea Pharmaceutica International AG Company Information
11.12.2 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Offered
11.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Basilea Pharmaceutica International AG Main Business Overview
11.12.5 Basilea Pharmaceutica International AG Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Community-acquired Bacterial Pneumonia Market Size 2018-2029
2.1.2 Community-acquired Bacterial Pneumonia Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Community-acquired Bacterial Pneumonia Segment by Type
2.2.1 Pleuromutilin Antibiotic
2.2.2 Cephalosporin
2.2.3 Glycylcycline
2.2.4 Oxazolidinone
2.2.5 Ketolide
2.2.6 Others
2.3 Community-acquired Bacterial Pneumonia Market Size by Type
2.3.1 Community-acquired Bacterial Pneumonia Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
2.4 Community-acquired Bacterial Pneumonia Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Community-acquired Bacterial Pneumonia Market Size by Application
2.5.1 Community-acquired Bacterial Pneumonia Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
3 COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA MARKET SIZE BY PLAYER
3.1 Community-acquired Bacterial Pneumonia Market Size Market Share by Players
3.1.1 Global Community-acquired Bacterial Pneumonia Revenue by Players (2018-2023)
3.1.2 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Players (2018-2023)
3.2 Global Community-acquired Bacterial Pneumonia Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA BY REGIONS
4.1 Community-acquired Bacterial Pneumonia Market Size by Regions (2018-2023)
4.2 Americas Community-acquired Bacterial Pneumonia Market Size Growth (2018-2023)
4.3 APAC Community-acquired Bacterial Pneumonia Market Size Growth (2018-2023)
4.4 Europe Community-acquired Bacterial Pneumonia Market Size Growth (2018-2023)
4.5 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023)
5.2 Americas Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023)
5.3 Americas Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Community-acquired Bacterial Pneumonia Market Size by Region (2018-2023)
6.2 APAC Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023)
6.3 APAC Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Community-acquired Bacterial Pneumonia by Country (2018-2023)
7.2 Europe Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023)
7.3 Europe Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Community-acquired Bacterial Pneumonia by Region (2018-2023)
8.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023)
8.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA MARKET FORECAST
10.1 Global Community-acquired Bacterial Pneumonia Forecast by Regions (2024-2029)
10.1.1 Global Community-acquired Bacterial Pneumonia Forecast by Regions (2024-2029)
10.1.2 Americas Community-acquired Bacterial Pneumonia Forecast
10.1.3 APAC Community-acquired Bacterial Pneumonia Forecast
10.1.4 Europe Community-acquired Bacterial Pneumonia Forecast
10.1.5 Middle East & Africa Community-acquired Bacterial Pneumonia Forecast
10.2 Americas Community-acquired Bacterial Pneumonia Forecast by Country (2024-2029)
10.2.1 United States Community-acquired Bacterial Pneumonia Market Forecast
10.2.2 Canada Community-acquired Bacterial Pneumonia Market Forecast
10.2.3 Mexico Community-acquired Bacterial Pneumonia Market Forecast
10.2.4 Brazil Community-acquired Bacterial Pneumonia Market Forecast
10.3 APAC Community-acquired Bacterial Pneumonia Forecast by Region (2024-2029)
10.3.1 China Community-acquired Bacterial Pneumonia Market Forecast
10.3.2 Japan Community-acquired Bacterial Pneumonia Market Forecast
10.3.3 Korea Community-acquired Bacterial Pneumonia Market Forecast
10.3.4 Southeast Asia Community-acquired Bacterial Pneumonia Market Forecast
10.3.5 India Community-acquired Bacterial Pneumonia Market Forecast
10.3.6 Australia Community-acquired Bacterial Pneumonia Market Forecast
10.4 Europe Community-acquired Bacterial Pneumonia Forecast by Country (2024-2029)
10.4.1 Germany Community-acquired Bacterial Pneumonia Market Forecast
10.4.2 France Community-acquired Bacterial Pneumonia Market Forecast
10.4.3 UK Community-acquired Bacterial Pneumonia Market Forecast
10.4.4 Italy Community-acquired Bacterial Pneumonia Market Forecast
10.4.5 Russia Community-acquired Bacterial Pneumonia Market Forecast
10.5 Middle East & Africa Community-acquired Bacterial Pneumonia Forecast by Region (2024-2029)
10.5.1 Egypt Community-acquired Bacterial Pneumonia Market Forecast
10.5.2 South Africa Community-acquired Bacterial Pneumonia Market Forecast
10.5.3 Israel Community-acquired Bacterial Pneumonia Market Forecast
10.5.4 Turkey Community-acquired Bacterial Pneumonia Market Forecast
10.5.5 GCC Countries Community-acquired Bacterial Pneumonia Market Forecast
10.6 Global Community-acquired Bacterial Pneumonia Forecast by Type (2024-2029)
10.7 Global Community-acquired Bacterial Pneumonia Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Nabriva Therapeutics
11.1.1 Nabriva Therapeutics Company Information
11.1.2 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Offered
11.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Nabriva Therapeutics Main Business Overview
11.1.5 Nabriva Therapeutics Latest Developments
11.2 Paratek Pharmaceuticals
11.2.1 Paratek Pharmaceuticals Company Information
11.2.2 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Offered
11.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Paratek Pharmaceuticals Main Business Overview
11.2.5 Paratek Pharmaceuticals Latest Developments
11.3 Melinta Therapeutics
11.3.1 Melinta Therapeutics Company Information
11.3.2 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Offered
11.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Melinta Therapeutics Main Business Overview
11.3.5 Melinta Therapeutics Latest Developments
11.4 Allergan plc
11.4.1 Allergan plc Company Information
11.4.2 Allergan plc Community-acquired Bacterial Pneumonia Product Offered
11.4.3 Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Allergan plc Main Business Overview
11.4.5 Allergan plc Latest Developments
11.5 Bayer AG
11.5.1 Bayer AG Company Information
11.5.2 Bayer AG Community-acquired Bacterial Pneumonia Product Offered
11.5.3 Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Bayer AG Main Business Overview
11.5.5 Bayer AG Latest Developments
11.6 Lupin Pharmaceuticals
11.6.1 Lupin Pharmaceuticals Company Information
11.6.2 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Offered
11.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Lupin Pharmaceuticals Main Business Overview
11.6.5 Lupin Pharmaceuticals Latest Developments
11.7 Mylan N.V.
11.7.1 Mylan N.V. Company Information
11.7.2 Mylan N.V. Community-acquired Bacterial Pneumonia Product Offered
11.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Mylan N.V. Main Business Overview
11.7.5 Mylan N.V. Latest Developments
11.8 Sanofi S.A.
11.8.1 Sanofi S.A. Company Information
11.8.2 Sanofi S.A. Community-acquired Bacterial Pneumonia Product Offered
11.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Sanofi S.A. Main Business Overview
11.8.5 Sanofi S.A. Latest Developments
11.9 Pfizer Inc.
11.9.1 Pfizer Inc. Company Information
11.9.2 Pfizer Inc. Community-acquired Bacterial Pneumonia Product Offered
11.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Pfizer Inc. Main Business Overview
11.9.5 Pfizer Inc. Latest Developments
11.10 Dainippon Sumitomo Pharma
11.10.1 Dainippon Sumitomo Pharma Company Information
11.10.2 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Offered
11.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Dainippon Sumitomo Pharma Main Business Overview
11.10.5 Dainippon Sumitomo Pharma Latest Developments
11.11 Takeda Pharmaceutical Company Limited
11.11.1 Takeda Pharmaceutical Company Limited Company Information
11.11.2 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Offered
11.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Takeda Pharmaceutical Company Limited Main Business Overview
11.11.5 Takeda Pharmaceutical Company Limited Latest Developments
11.12 Basilea Pharmaceutica International AG
11.12.1 Basilea Pharmaceutica International AG Company Information
11.12.2 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Offered
11.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Basilea Pharmaceutica International AG Main Business Overview
11.12.5 Basilea Pharmaceutica International AG Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Community-acquired Bacterial Pneumonia Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Pleuromutilin Antibiotic
Table 3. Major Players of Cephalosporin
Table 4. Major Players of Glycylcycline
Table 5. Major Players of Oxazolidinone
Table 6. Major Players of Ketolide
Table 7. Major Players of Others
Table 8. Community-acquired Bacterial Pneumonia Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 9. Global Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & ($ Millions)
Table 10. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Table 11. Community-acquired Bacterial Pneumonia Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 12. Global Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & ($ Millions)
Table 13. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Table 14. Global Community-acquired Bacterial Pneumonia Revenue by Players (2018-2023) & ($ Millions)
Table 15. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Player (2018-2023)
Table 16. Community-acquired Bacterial Pneumonia Key Players Head office and Products Offered
Table 17. Community-acquired Bacterial Pneumonia Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Community-acquired Bacterial Pneumonia Market Size by Regions 2018-2023 & ($ Millions)
Table 21. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Regions (2018-2023)
Table 22. Global Community-acquired Bacterial Pneumonia Revenue by Country/Region (2018-2023) & ($ millions)
Table 23. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Country/Region (2018-2023)
Table 24. Americas Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023) & ($ Millions)
Table 25. Americas Community-acquired Bacterial Pneumonia Market Size Market Share by Country (2018-2023)
Table 26. Americas Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & ($ Millions)
Table 27. Americas Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Table 28. Americas Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & ($ Millions)
Table 29. Americas Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Table 30. APAC Community-acquired Bacterial Pneumonia Market Size by Region (2018-2023) & ($ Millions)
Table 31. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Region (2018-2023)
Table 32. APAC Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & ($ Millions)
Table 33. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Table 34. APAC Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & ($ Millions)
Table 35. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Table 36. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023) & ($ Millions)
Table 37. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Country (2018-2023)
Table 38. Europe Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & ($ Millions)
Table 39. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Table 40. Europe Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & ($ Millions)
Table 41. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Table 42. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Region (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Region (2018-2023)
Table 44. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & ($ Millions)
Table 45. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Table 46. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & ($ Millions)
Table 47. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Table 48. Key Market Drivers & Growth Opportunities of Community-acquired Bacterial Pneumonia
Table 49. Key Market Challenges & Risks of Community-acquired Bacterial Pneumonia
Table 50. Key Industry Trends of Community-acquired Bacterial Pneumonia
Table 51. Global Community-acquired Bacterial Pneumonia Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 52. Global Community-acquired Bacterial Pneumonia Market Size Market Share Forecast by Regions (2024-2029)
Table 53. Global Community-acquired Bacterial Pneumonia Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 54. Global Community-acquired Bacterial Pneumonia Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 55. Nabriva Therapeutics Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 56. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Offered
Table 57. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 58. Nabriva Therapeutics Main Business
Table 59. Nabriva Therapeutics Latest Developments
Table 60. Paratek Pharmaceuticals Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 61. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Offered
Table 62. Paratek Pharmaceuticals Main Business
Table 63. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 64. Paratek Pharmaceuticals Latest Developments
Table 65. Melinta Therapeutics Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 66. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Offered
Table 67. Melinta Therapeutics Main Business
Table 68. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 69. Melinta Therapeutics Latest Developments
Table 70. Allergan plc Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 71. Allergan plc Community-acquired Bacterial Pneumonia Product Offered
Table 72. Allergan plc Main Business
Table 73. Allergan plc Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 74. Allergan plc Latest Developments
Table 75. Bayer AG Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 76. Bayer AG Community-acquired Bacterial Pneumonia Product Offered
Table 77. Bayer AG Main Business
Table 78. Bayer AG Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 79. Bayer AG Latest Developments
Table 80. Lupin Pharmaceuticals Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 81. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Offered
Table 82. Lupin Pharmaceuticals Main Business
Table 83. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 84. Lupin Pharmaceuticals Latest Developments
Table 85. Mylan N.V. Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 86. Mylan N.V. Community-acquired Bacterial Pneumonia Product Offered
Table 87. Mylan N.V. Main Business
Table 88. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 89. Mylan N.V. Latest Developments
Table 90. Sanofi S.A. Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 91. Sanofi S.A. Community-acquired Bacterial Pneumonia Product Offered
Table 92. Sanofi S.A. Main Business
Table 93. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 94. Sanofi S.A. Latest Developments
Table 95. Pfizer Inc. Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 96. Pfizer Inc. Community-acquired Bacterial Pneumonia Product Offered
Table 97. Pfizer Inc. Main Business
Table 98. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 99. Pfizer Inc. Latest Developments
Table 100. Dainippon Sumitomo Pharma Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 101. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Offered
Table 102. Dainippon Sumitomo Pharma Main Business
Table 103. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 104. Dainippon Sumitomo Pharma Latest Developments
Table 105. Takeda Pharmaceutical Company Limited Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 106. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Offered
Table 107. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 108. Takeda Pharmaceutical Company Limited Main Business
Table 109. Takeda Pharmaceutical Company Limited Latest Developments
Table 110. Basilea Pharmaceutica International AG Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 111. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Offered
Table 112. Basilea Pharmaceutica International AG Main Business
Table 113. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 114. Basilea Pharmaceutica International AG Latest Developments
Table 1. Community-acquired Bacterial Pneumonia Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Pleuromutilin Antibiotic
Table 3. Major Players of Cephalosporin
Table 4. Major Players of Glycylcycline
Table 5. Major Players of Oxazolidinone
Table 6. Major Players of Ketolide
Table 7. Major Players of Others
Table 8. Community-acquired Bacterial Pneumonia Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 9. Global Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & ($ Millions)
Table 10. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Table 11. Community-acquired Bacterial Pneumonia Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 12. Global Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & ($ Millions)
Table 13. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Table 14. Global Community-acquired Bacterial Pneumonia Revenue by Players (2018-2023) & ($ Millions)
Table 15. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Player (2018-2023)
Table 16. Community-acquired Bacterial Pneumonia Key Players Head office and Products Offered
Table 17. Community-acquired Bacterial Pneumonia Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Community-acquired Bacterial Pneumonia Market Size by Regions 2018-2023 & ($ Millions)
Table 21. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Regions (2018-2023)
Table 22. Global Community-acquired Bacterial Pneumonia Revenue by Country/Region (2018-2023) & ($ millions)
Table 23. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Country/Region (2018-2023)
Table 24. Americas Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023) & ($ Millions)
Table 25. Americas Community-acquired Bacterial Pneumonia Market Size Market Share by Country (2018-2023)
Table 26. Americas Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & ($ Millions)
Table 27. Americas Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Table 28. Americas Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & ($ Millions)
Table 29. Americas Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Table 30. APAC Community-acquired Bacterial Pneumonia Market Size by Region (2018-2023) & ($ Millions)
Table 31. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Region (2018-2023)
Table 32. APAC Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & ($ Millions)
Table 33. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Table 34. APAC Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & ($ Millions)
Table 35. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Table 36. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023) & ($ Millions)
Table 37. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Country (2018-2023)
Table 38. Europe Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & ($ Millions)
Table 39. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Table 40. Europe Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & ($ Millions)
Table 41. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Table 42. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Region (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Region (2018-2023)
Table 44. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & ($ Millions)
Table 45. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Table 46. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & ($ Millions)
Table 47. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Table 48. Key Market Drivers & Growth Opportunities of Community-acquired Bacterial Pneumonia
Table 49. Key Market Challenges & Risks of Community-acquired Bacterial Pneumonia
Table 50. Key Industry Trends of Community-acquired Bacterial Pneumonia
Table 51. Global Community-acquired Bacterial Pneumonia Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 52. Global Community-acquired Bacterial Pneumonia Market Size Market Share Forecast by Regions (2024-2029)
Table 53. Global Community-acquired Bacterial Pneumonia Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 54. Global Community-acquired Bacterial Pneumonia Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 55. Nabriva Therapeutics Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 56. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Offered
Table 57. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 58. Nabriva Therapeutics Main Business
Table 59. Nabriva Therapeutics Latest Developments
Table 60. Paratek Pharmaceuticals Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 61. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Offered
Table 62. Paratek Pharmaceuticals Main Business
Table 63. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 64. Paratek Pharmaceuticals Latest Developments
Table 65. Melinta Therapeutics Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 66. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Offered
Table 67. Melinta Therapeutics Main Business
Table 68. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 69. Melinta Therapeutics Latest Developments
Table 70. Allergan plc Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 71. Allergan plc Community-acquired Bacterial Pneumonia Product Offered
Table 72. Allergan plc Main Business
Table 73. Allergan plc Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 74. Allergan plc Latest Developments
Table 75. Bayer AG Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 76. Bayer AG Community-acquired Bacterial Pneumonia Product Offered
Table 77. Bayer AG Main Business
Table 78. Bayer AG Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 79. Bayer AG Latest Developments
Table 80. Lupin Pharmaceuticals Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 81. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Offered
Table 82. Lupin Pharmaceuticals Main Business
Table 83. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 84. Lupin Pharmaceuticals Latest Developments
Table 85. Mylan N.V. Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 86. Mylan N.V. Community-acquired Bacterial Pneumonia Product Offered
Table 87. Mylan N.V. Main Business
Table 88. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 89. Mylan N.V. Latest Developments
Table 90. Sanofi S.A. Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 91. Sanofi S.A. Community-acquired Bacterial Pneumonia Product Offered
Table 92. Sanofi S.A. Main Business
Table 93. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 94. Sanofi S.A. Latest Developments
Table 95. Pfizer Inc. Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 96. Pfizer Inc. Community-acquired Bacterial Pneumonia Product Offered
Table 97. Pfizer Inc. Main Business
Table 98. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 99. Pfizer Inc. Latest Developments
Table 100. Dainippon Sumitomo Pharma Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 101. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Offered
Table 102. Dainippon Sumitomo Pharma Main Business
Table 103. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 104. Dainippon Sumitomo Pharma Latest Developments
Table 105. Takeda Pharmaceutical Company Limited Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 106. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Offered
Table 107. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 108. Takeda Pharmaceutical Company Limited Main Business
Table 109. Takeda Pharmaceutical Company Limited Latest Developments
Table 110. Basilea Pharmaceutica International AG Details, Company Type, Community-acquired Bacterial Pneumonia Area Served and Its Competitors
Table 111. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Offered
Table 112. Basilea Pharmaceutica International AG Main Business
Table 113. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 114. Basilea Pharmaceutica International AG Latest Developments
LIST OF FIGURES
Figure 1. Community-acquired Bacterial Pneumonia Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Community-acquired Bacterial Pneumonia Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Community-acquired Bacterial Pneumonia Sales Market Share by Country/Region (2022)
Figure 8. Community-acquired Bacterial Pneumonia Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Type in 2022
Figure 10. Community-acquired Bacterial Pneumonia in Hospital Pharmacies
Figure 11. Global Community-acquired Bacterial Pneumonia Market: Hospital Pharmacies (2018-2023) & ($ Millions)
Figure 12. Community-acquired Bacterial Pneumonia in Retail Pharmacies
Figure 13. Global Community-acquired Bacterial Pneumonia Market: Retail Pharmacies (2018-2023) & ($ Millions)
Figure 14. Community-acquired Bacterial Pneumonia in Online Pharmacies
Figure 15. Global Community-acquired Bacterial Pneumonia Market: Online Pharmacies (2018-2023) & ($ Millions)
Figure 16. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Application in 2022
Figure 17. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Player in 2022
Figure 18. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Community-acquired Bacterial Pneumonia Market Size 2018-2023 ($ Millions)
Figure 20. APAC Community-acquired Bacterial Pneumonia Market Size 2018-2023 ($ Millions)
Figure 21. Europe Community-acquired Bacterial Pneumonia Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size 2018-2023 ($ Millions)
Figure 23. Americas Community-acquired Bacterial Pneumonia Value Market Share by Country in 2022
Figure 24. United States Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Region in 2022
Figure 29. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Type in 2022
Figure 30. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Application in 2022
Figure 31. China Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Country in 2022
Figure 38. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Figure 39. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Figure 40. Germany Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 54. APAC Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 55. Europe Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 57. United States Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 58. Canada Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 61. China Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 62. Japan Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 63. Korea Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 65. India Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 66. Australia Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 67. Germany Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 68. France Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 69. UK Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 70. Italy Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 71. Russia Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 72. Spain Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 75. Israel Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 78. Global Community-acquired Bacterial Pneumonia Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Community-acquired Bacterial Pneumonia Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Community-acquired Bacterial Pneumonia Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Community-acquired Bacterial Pneumonia Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Community-acquired Bacterial Pneumonia Sales Market Share by Country/Region (2022)
Figure 8. Community-acquired Bacterial Pneumonia Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Type in 2022
Figure 10. Community-acquired Bacterial Pneumonia in Hospital Pharmacies
Figure 11. Global Community-acquired Bacterial Pneumonia Market: Hospital Pharmacies (2018-2023) & ($ Millions)
Figure 12. Community-acquired Bacterial Pneumonia in Retail Pharmacies
Figure 13. Global Community-acquired Bacterial Pneumonia Market: Retail Pharmacies (2018-2023) & ($ Millions)
Figure 14. Community-acquired Bacterial Pneumonia in Online Pharmacies
Figure 15. Global Community-acquired Bacterial Pneumonia Market: Online Pharmacies (2018-2023) & ($ Millions)
Figure 16. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Application in 2022
Figure 17. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Player in 2022
Figure 18. Global Community-acquired Bacterial Pneumonia Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Community-acquired Bacterial Pneumonia Market Size 2018-2023 ($ Millions)
Figure 20. APAC Community-acquired Bacterial Pneumonia Market Size 2018-2023 ($ Millions)
Figure 21. Europe Community-acquired Bacterial Pneumonia Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size 2018-2023 ($ Millions)
Figure 23. Americas Community-acquired Bacterial Pneumonia Value Market Share by Country in 2022
Figure 24. United States Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Region in 2022
Figure 29. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Type in 2022
Figure 30. APAC Community-acquired Bacterial Pneumonia Market Size Market Share by Application in 2022
Figure 31. China Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Country in 2022
Figure 38. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Figure 39. Europe Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Figure 40. Germany Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Community-acquired Bacterial Pneumonia Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 54. APAC Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 55. Europe Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 57. United States Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 58. Canada Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 61. China Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 62. Japan Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 63. Korea Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 65. India Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 66. Australia Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 67. Germany Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 68. France Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 69. UK Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 70. Italy Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 71. Russia Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 72. Spain Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 75. Israel Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Community-acquired Bacterial Pneumonia Market Size 2024-2029 ($ Millions)
Figure 78. Global Community-acquired Bacterial Pneumonia Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Community-acquired Bacterial Pneumonia Market Size Market Share Forecast by Application (2024-2029)
